220 related articles for article (PubMed ID: 38605021)
21. Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET).
Lamberti G; Prinzi N; Bongiovanni A; Torniai M; Andrini E; Biase D; Malvi D; Mosca M; Berardi R; Ibrahim T; Pusceddu S; Campana D
Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174986
[TBL] [Abstract][Full Text] [Related]
22. All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update.
Chatzipanagiotou O; Schizas D; Vailas M; Tsoli M; Sakarellos P; Sotiropoulou M; Papalambros A; Felekouras E
J Neuroendocrinol; 2023 Apr; 35(4):e13267. PubMed ID: 37042078
[TBL] [Abstract][Full Text] [Related]
23. Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors.
Sebastian-Valles F; Bernaldo Madrid B; Sager C; Carrillo López E; Mera Carreiro S; Ávila Antón L; García NS; Sampedro-Nuñez MA; Díaz Pérez JÁ; Marazuela M
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979851
[TBL] [Abstract][Full Text] [Related]
24. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma.
Sorbye H; Grande E; Pavel M; Tesselaar M; Fazio N; Reed NS; Knigge U; Christ E; Ambrosini V; Couvelard A; Tiensuu Janson E
J Neuroendocrinol; 2023 Mar; 35(3):e13249. PubMed ID: 36924180
[TBL] [Abstract][Full Text] [Related]
25. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?
Garcia-Carbonero R; Anton-Pascual B; Modrego A; Del Carmen Riesco-Martinez M; Lens-Pardo A; Carretero-Puche C; Rubio-Cuesta B; Soldevilla B
Endocr Rev; 2023 Jul; 44(4):724-736. PubMed ID: 36879384
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of [
Mitjavila M; Jimenez-Fonseca P; Belló P; Pubul V; Percovich JC; Garcia-Burillo A; Hernando J; Arbizu J; Rodeño E; Estorch M; Llana B; Castellón M; García-Cañamaque L; Gajate P; Riesco MC; Miguel MB; Balaguer-Muñoz D; Custodio A; Cano JM; Repetto A; Garcia-Alonso P; Muros MA; Vercher-Conejero JL; Carmona-Bayonas A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2486-2500. PubMed ID: 36877234
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology of Gastric Malignancies 2000-2018 According to Histology: A Population-Based Analysis of Incidence and Temporal Trends.
Rustgi SD; McKinley M; McBay B; Zylberberg HM; Gomez SL; Hur C; Kastrinos F; Gupta S; Kim MK; Itzkowitz SH; Shah SC
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3285-3295.e8. PubMed ID: 36792000
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Walter T; Lievre A; Coriat R; Malka D; Elhajbi F; Di Fiore F; Hentic O; Smith D; Hautefeuille V; Roquin G; Perrier M; Dahan L; Granger V; Sobhani I; Mineur L; Niccoli P; Assenat E; Scoazec JY; Le Malicot K; Lepage C; Lombard-Bohas C
Lancet Oncol; 2023 Mar; 24(3):297-306. PubMed ID: 36739879
[TBL] [Abstract][Full Text] [Related]
29. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors.
Hope TA; Allen-Auerbach M; Bodei L; Calais J; Dahlbom M; Dunnwald LK; Graham MM; Jacene HA; Heath CL; Mittra ES; Wright CL; Fendler WP; Herrmann K; Taïeb D; Kjaer A
J Nucl Med; 2023 Feb; 64(2):204-210. PubMed ID: 36725249
[No Abstract] [Full Text] [Related]
30. Ga-68 DOTATATE PET/CT in a patient with Zollinger-Ellison syndrome.
Jayasekera M; Sartin S; Bhargava P
Radiol Case Rep; 2023 Mar; 18(3):1046-1048. PubMed ID: 36684643
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review.
Zappi A; Persano I; Galvani L; Parlagreco E; Andrini E; Campana D; Brizzi MP; Lamberti G; La Salvia A
J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675645
[TBL] [Abstract][Full Text] [Related]
32. Dual [
Chan DL; Hayes AR; Karfis I; Conner A; Furtado O'Mahony L; Mileva M; Bernard E; Roach P; Marin G; Pavlakis N; Schembri G; Gnanasegaran G; Marin C; Vanderlinden B; Navalkissoor S; Caplin ME; Flamen P; Toumpanakis C; Bailey DL
Br J Cancer; 2023 Feb; 128(4):549-555. PubMed ID: 36434154
[TBL] [Abstract][Full Text] [Related]
33. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study.
White BE; Rous B; Chandrakumaran K; Wong K; Bouvier C; Van Hemelrijck M; George G; Russell B; Srirajaskanthan R; Ramage JK
Lancet Reg Health Eur; 2022 Dec; 23():100510. PubMed ID: 36176500
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C; Machida N; Honma Y; Okusaka T; Boku N; Kato K; Nomura S; Hiraoka N; Sekine S; Taniguchi H; Okano N; Yamaguchi K; Sato T; Ikeda M; Mizuno N; Ozaka M; Kataoka T; Ueno M; Kitagawa Y; Terashima M; Furuse J;
JAMA Oncol; 2022 Oct; 8(10):1447-1455. PubMed ID: 35980649
[TBL] [Abstract][Full Text] [Related]
35. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G
Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
Maio M; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Xu L; Jin F; Norwood K; Marabelle A
Ann Oncol; 2022 Sep; 33(9):929-938. PubMed ID: 35680043
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection.
Ye H; Yuan Y; Chen P; Zheng Q
Surg Endosc; 2022 Aug; 36(8):6162-6169. PubMed ID: 35507062
[TBL] [Abstract][Full Text] [Related]
38. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas.
Dasari A; Shen C; Devabhaktuni A; Nighot R; Sorbye H
Oncologist; 2022 Apr; 27(4):299-306. PubMed ID: 35380711
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series.
Rinzivillo M; Panzuto F; Esposito G; Lahner E; Signore A; Annibale B
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329967
[TBL] [Abstract][Full Text] [Related]
40. Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review.
Gosain R; Gupta M; Roy AM; Strosberg J; Glaser KM; Iyer R
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
